MARKET

SNCA

SNCA

Seneca Biopharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.6000
-0.0070
-1.15%
After Hours: 0.6002 +0.0002 +0.03% 16:48 11/27 EST
OPEN
0.6100
PREV CLOSE
0.6070
HIGH
0.6190
LOW
0.5800
VOLUME
258.94K
TURNOVER
--
52 WEEK HIGH
4.090
52 WEEK LOW
0.5000
MARKET CAP
10.38M
P/E (TTM)
-0.3658
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Inside Sierra Nevada Corp's space plans, from the reusable 'Dream Chaser' to inflatable habitats
Sierra Nevada Corporation is investing heavily in space, especially as it sees NASA and other companies building infrastructure in orbit.
CNBC.com · 10/11 10:57
Seneca Biopharma, Inc. Announces Completion Of Phase II Clinical Study In China For The Treatment Of Ischemic Stroke
GERMANTOWN, Md., Sept. 10, 2020 /PRNewswire/ --Seneca Biopharma, Inc. (NASDAQ:SNCA), a biopharmaceutical company focused on developing novel treatments for diseases of high unmet medical need, today announced
Benzinga · 09/10 12:12
Seneca Biopharma, Inc. Announces Completion of Phase II Clinical Study in China for the Treatment of Ischemic Stroke
Seneca Biopharma, Inc. (Nasdaq: SNCA), a biopharmaceutical company focused on developing novel treatments for diseases of high unmet medical need, today announced that the last subject completed their final follow-up assessment in the Company's non-GCP Phase II study in Beijing, China evaluating
PR Newswire · 09/10 12:00
Letter from Seneca Biopharma's Executive Chairman
Seneca Biopharma, Inc. (Nasdaq: SNCA), a biopharmaceutical company focused on developing novel treatments for diseases of high unmet medical need, today provided the following letter from Dr. Ken Carter, the Company's Executive Chairman.
PR Newswire · 09/02 12:00
Seneca Biopharma shares are trading higher after the company reported Q2 EPS results up from last year.
Benzinga · 08/13 17:32
Seneca Biopharma reports Q2 results
Seneca Biopharma (SNCA): Q2 GAAP EPS of -$0.15.At June 30, cash was ~$15.8M as compared to ~$10M at March 31, 2020.Press Release
Seekingalpha · 08/13 12:29
Seneca Biopharma reports Q2 results
Seneca Biopharma (SNCA): Q2 GAAP EPS of -$0.15.At June 30, cash was ~$15.8M as compared to ~$10M at March 31, 2020.Press Release
Seekingalpha · 08/13 12:29
Seneca Biopharma Q2 EPS $(0.15) Up From $(1.45) YoY
Seneca Biopharma (NASDAQ:SNCA) reported quarterly losses of $(0.15) per share. This is a 89.66 percent increase over losses of $(1.45) per share from the same period last year.
Benzinga · 08/13 12:21
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SNCA. Analyze the recent business situations of Seneca Biopharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Price Target
The average SNCA stock price target is 26.00 with a high estimate of 26.00 and a low estimate of 26.00.
EPS
Institutional Holdings
Institutions: 41
Institutional Holdings: 947.18K
% Owned: 5.48%
Shares Outstanding: 17.30M
TypeInstitutionsShares
Increased
4
278.54K
New
10
147.31K
Decreased
2
198.24K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.18%
Pharmaceuticals & Medical Research
+1.72%
Key Executives
Chairman/Chief Executive Officer/Executive Director
Kenneth Carter
President/Chief Operating Officer
Matthew Kalnik
Other
David Recker
Chief Financial Officer/Chief Accounting Officer
Dane Saglio
Director
Mary Gray
Director
David Mazzo
Independent Director
Cristina Csimma
Independent Director
Scott Ogilvie
Independent Director
Sandford Smith
Independent Director
Binxian Wei
Independent Director
Stanley Westreich
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About SNCA
Seneca Biopharma, Inc., formerly Neuralstem, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing treatments for diseases of unmet medical need. It is focused on finding and acquiring new assets, sciences and technologies that provide therapies for patients. It intends to focus on developing a pipeline of biopharmaceuticals and commercializing those products.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Seneca Biopharma Inc stock information, including NASDAQ:SNCA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SNCA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SNCA stock methods without spending real money on the virtual paper trading platform.